Clinical Trials on Fallopian Tubes Cancer in Canada

Total 3724 results

National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
University Health Network, Toronto
Merck Sharp & Dohme LLC; ImmunoVaccine Technologies, Inc. (IMV Inc.)

Active, not recruiting

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Advanced Cancer | Primary Peritoneal Carcinoma

Canada
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Canada
University Health Network, Toronto

Withdrawn

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Endometrioid Tumor | TP53 Mutation

Canada
British Columbia Cancer Agency
Ozmosis Research Inc.

Unknown

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Canada
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Canada
European Organisation for Research and Treatment...

Completed

Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

France, Canada, Spain, Norway, Belgium, Netherlands, United Kingdom, Portugal, Austria, Denmark, Ireland, Sweden, Italy, Argentina, Germany
AltaRex

Unknown

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Incyte Corporation

Active, not recruiting

Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Cancer | Recurrent Epithelial Ovarian Cancer | Recurrent Peritoneal Cancer

United States, Canada
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage IV Primary Peritoneal Cancer

United States, Canada
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Canada
University Health Network, Toronto
GlaxoSmithKline

Recruiting

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Cancer | High Grade Endometrioid Cancer

Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
University Health Network, Toronto

Active, not recruiting

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer | Recurrent | Platinum-resistant

Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous... and other conditions

United States, Korea, Republic of, Canada, Japan
University Health Network, Toronto

Completed

A Study of Long-Term Responders on Olaparib (OLALA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Canada, Spain, Australia, Italy, United Kingdom
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

Canada, United States
NCIC Clinical Trials Group

Completed

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
University Health Network, Toronto

Terminated

Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Bowel Obstruction

Canada
National Cancer Institute (NCI)

Completed

Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States, Canada
University Health Network, Toronto

Active, not recruiting

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NEO)

Ovarian Cancer | Fallopian Tube Cancer | Neoadjuvant Treatment | Debulking Surgical Procedures

Canada, United Kingdom, Spain, New Zealand
Nordic Society of Gynaecological Oncology - Clinical...
European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical...

Completed

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

Italy, Canada, Israel, Norway, Belgium, Netherlands, Denmark, Portugal, Spain, United States
AltaRex

Unknown

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
NCIC Clinical Trials Group

Completed

Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada, United Kingdom
NCIC Clinical Trials Group
European Organisation for Research and Treatment of Cancer - EORTC; Grupo Español...

Completed

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada
Pfizer

Completed

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma and other conditions

United States, Korea, Republic of, Canada
Shattuck Labs, Inc.

Active, not recruiting

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma

United States, United Kingdom, Spain, Canada
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditions

United States, Canada, Korea, Republic of, Puerto Rico, Ireland
ImmunoGen, Inc.
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Canada, Germany, China, France, Korea, Republic of, Belgium, United Kingdom, Serbia, Spain, Australia, Israel, Italy, Taiwan, Czechia, Bulgaria, Netherlands, Portugal, Poland, Russian Federation, Ukraine
National Cancer Institute (NCI)

Completed

Phase II ABT-888 With Cyclophosphamide

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Triple-Negative Breast Cancer | Serous Carcinoma Cancer

United States, Canada
Grupo Español de Investigación en Cáncer de Ovario

Completed

Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

Spain
ImmunoGen, Inc.
Gynecologic Oncology Group

Completed

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan
Pfizer

Terminated

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Low-grade Serous Ovarian Cancer | Low-grade Serous Fallopian Tube Cancer | Low-grade Serous Peritoneal Cancer

United States, Canada, Hungary, Spain, Belgium, France, United Kingdom, Australia, Czechia, Netherlands, Sweden, Italy, Denmark, Germany, Austria, Finland, Ireland, Norway, Poland
ImmunoGen, Inc.

Completed

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Belgium, Canada
Novartis Pharmaceuticals

Completed

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Greece, Canada, Finland, Italy, Spain, United Kingdom, France, Denmark, South Africa, Australia, Poland
Imunon

Active, not recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Canada
pharmaand GmbH

Completed

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Other Solid Tumor | Metastatic Castration-Resistant Prostate Cancer

Israel, Italy, Canada, Russian Federation, United Kingdom, Poland
Amgen

Terminated

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, Belgium, Germany, Italy, United Kingdom, Canada, Denmark, Switzerland, Hong Kong, Austria, Slovakia, Taiwan, Hungary, France, Singapore, Australia, Poland, New Zealand
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Advanced Solid Tumor With Evidence of Germline or Somatic BRCA

United States, Israel, Spain, Canada, United Kingdom
AstraZeneca

Completed

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

United States, Canada, Netherlands
GlaxoSmithKline

Completed

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Neoplasms, Ovarian

United States, Canada
Mersana Therapeutics
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Terminated

Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (UP-NEXT)

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer

United States, Australia, Canada
ImmunoGen, Inc.

Active, not recruiting

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, France, Belgium, Spain, Ireland, Italy, Australia, Canada
Canadian Cancer Trials Group
National Cancer Institute (NCI); Cancer Research UK; Grupo Español de Investigación... and other collaborators

Completed

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer | Metastatic Cancer

Canada, Spain, United States, United Kingdom
Mural Oncology, Inc
Merck Sharp & Dohme LLC

Recruiting

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Taiwan, Canada, Israel, France, United Kingdom, Germany, Belgium, Czechia, Singapore, Australia, Austria, Italy
Sutro Biopharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Australia, Korea, Republic of, Israel, Singapore, Canada

Clinical Trials on Fallopian Tubes Cancer in Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations